{"id":54775,"date":"2023-03-13T17:08:00","date_gmt":"2023-03-13T16:08:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/celmatix-and-global-collaborators-announce-findings-from-largest-genetic-study-to-date-on-endometriosis\/"},"modified":"2023-03-13T17:08:00","modified_gmt":"2023-03-13T16:08:00","slug":"celmatix-and-global-collaborators-announce-findings-from-largest-genetic-study-to-date-on-endometriosis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/celmatix-and-global-collaborators-announce-findings-from-largest-genetic-study-to-date-on-endometriosis\/","title":{"rendered":"Celmatix and Global Collaborators Announce Findings from Largest Genetic Study to Date on Endometriosis"},"content":{"rendered":"
\n

\nResults reveal genetic basis of disease and link to other chronic pain conditions such as migraine and back pain that have implications for novel drug interventions<\/i>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–Celmatix Inc., the leading women\u2019s health biotech focused on ovarian biology, today announced findings from its long-term collaboration with researchers from the University of Oxford and 24 other institutions to decode the genetic basis of endometriosis, a condition that globally impacts 1 in 10 women*. The study, published today in Nature Genetics, is the largest study on endometriosis genetics conducted to date and includes DNA from 60,600 women with endometriosis and 701,900 controls. Findings from the study demonstrate a shared genetic basis for endometriosis and other types of pain seemingly unrelated to endometriosis, including migraine, back pain and multi-site pain. The study also reveals that ovarian endometriosis has a different genetic basis from other disease manifestations. The results open up new avenues for designing new medical treatments targeting subtypes of endometriosis, or even the repurposing of existing pain treatments for endometriosis.\n<\/p>\n

<\/a><\/p>\n

\nAbout Endometriosis:<\/b>\n<\/p>\n

\nEndometriosis has enormous implications for the quality of a woman\u2019s life. This severe inflammatory condition, occurring in 5-10% of women of reproductive age (190 million globally), can cause chronic and intense pelvic pain, dysmenorrhea, dyspareunia, cyclic gastrointestinal or urinary symptoms, hematuria, fatigue, depression, anxiety, and infertility. Endometriosis has also been shown to increase the risk of cardiovascular disease systemic lupus erythematosus, rheumatoid arthritis, and impaired quality of life in relation to pain, psychological and social functioning.\n<\/p>\n

\nIt is characterized by the presence of tissue that resembles the uterine lining (endometrium) outside of the uterus. The location of these endometriotic deposits is primarily on organs within the pelvis (e.g. ovaries, pelvic surfaces and ligaments, bowel or bladder), although more rarely it can also be found outside of the pelvis. The huge impact on the health of many women is compounded by the fact that endometriosis can only reliably be diagnosed through surgery, and there is on average an 8-year delay to diagnosis and treatment from the first onset of symptoms. Treatment is limited to repeated surgeries and hormonal treatments with multiple side-effects.\n<\/p>\n

\nStudy Findings:<\/b>\n<\/p>\n

\nWhile it has been known that endometriosis can run in families and there is a genetic component, very little was known about the causes of endometriosis and how these genetics play a role.\n<\/p>\n

\nFindings from the landmark study revealed:\n<\/p>\n